Instrumento Inactivo

Otros idiomas TrovaGene Inc Nasdaq

Acciones

US8972383090

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Cardiff Oncology: Q1 Earnings Snapshot	02/05
Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update	02/05
Cardiff Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	02/05
Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update	25/04
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study	08/04
Cardiff Oncology Presents Novel Preclinical Data At Aacr Annual Meeting 2024 That Supports Ongoing First-Line Ras-Mutated Mcrc Clinical Study	08/04
Thinking about buying stock in Cardiff Oncology, BIOLASE, Akebia Therapeutics, Astera Labs, or Atossa Therapeutics?	26/03
Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024	06/03
Sector Update: Health Care Stocks Rising Late Afternoon	01/03
Sector Update: Health Care	01/03
Cardiff Oncology Shares Jump, Discontinued Cancer Treatment Trial Shows Efficacy	01/03
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update	29/02
Cardiff Oncology, Inc. Announces First Patient Dosed in Randomized First-Line RAS-Mutated Metastatic Colorectal Cancer Trial (CRDF-004)	29/02
Cardiff Oncology, Inc. Provides Clinical Update on Phase 2 Randomized Second-Line ONSEMBLE Trial in Patients with RAS-Mutated mCRC	29/02
Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC	29/02
Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)	29/02
Cardiff Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference	26/02
Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference	26/02
Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update	22/02

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas TrovaGene Inc Nasdaq

Acciones

US8972383090

Otros idiomas

Filtros